



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE,
VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA
TEL: 0260-2430027 / 2400639
E-mail: hbm@gtbl.in

GTBL/BSE/NSE/2025-26/46

5th February, 2026

BSE Limited

25, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code – 506879

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400051
Symbol: GUJTHEM

Dear Sir / Madam,

Sub: Outcome of the Board Meeting under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Meeting Commencement time : 11: 30 A.M.
Meeting Conclusion Time : 04.00 P.M.

The Board of Directors at its meeting held today, have inter alia, transacted the following items of businesses:

- a) Approved the Unaudited Financial Results for the quarter and nine months ended 31st December, 2025 together with the Limited Review Report of M/s. GMJ & Co., Chartered Accountants, which are attached herewith.
- b) The Board on the recommendation of the Nomination & Remuneration Committee, has approved the re-appointment of Ms. Kirandeep Madan (DIN: 00686547) as Non-Executive Woman Independent Director of the Company for the second term of five consecutive years, commencing from 1st May, 2026 to 30th April, 2031, subject to the approval of the shareholders of the Company. Details are mentioned in the attached Annexure.
- c) Considering the functional requirements of the Company, Mr. Bhavik Shah Chief Financial Officer, is transitioning into a different role within the organization. Based on the recommendation of the Nomination & Remuneration Committee and in order to strengthen the finance function, the Board approved the appointment of Mr. Krupesh Patel as Chief Financial Officer & Key Managerial Personnel of the Company with effect from 1st April 2026, pursuant to Section 203 of the Companies Act 2013 and applicable provisions of SEBI Listing Obligations and Disclosure Regulations. Details are mentioned in the attached Annexure.

We request you to take the above on record please.

Thanking you,

Yours faithfully,

For Gujarat Themis Biosyn Limited

Vineet Gawankar
Company Secretary & Compliance Officer



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE,

VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA

TEL: 0260-2430027 / 2400639

E-mail: hbm@gtbl.in

Annexure

Disclosure under sub-para (7) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Particulars	Ms. Kirandeep Madan (DIN: 00686547) Woman Independent Director	Mr. Krupesh Patel, CFO & KMP	Mr. Bhavik Shah, CFO & KMP
Reason for change	Re-appointment	Appointment	Resignation
Date of change	1 st May, 2026	1 st April, 2026	1 st April, 2026
Brief Profile (in case of appointment)	Ms. Kirandeep Madan is a Physiotherapist and Sociologist by education. She has been involved in social work for over 25 years, working closely with children, women and senior citizens on health, environment, civic and governance issues. She was associated with AGNI i (Action for Good Governance & Networking in India), a wellknown NGO in Mumbai, for over 9 years. During this period, apart from coordinating the activities of the NGO, she authored 3 citizens' guides on the Fundamentals of Voting and The Right to information Act, among other key projects.	Krupesh Patel is a seasoned professional with 15 years of extensive experience spanning the pharmaceutical, steel, consumer durables, and defense sectors. Currently serving as Assistant General Manager with Themis Medicare Limited since October 2024. He has worked with premier organizations such as Tata Advanced Systems, Blue Star, Wockhardt, Lupin, and Essar Steel. His professional journey is underpinned by a distinguished academic foundation, holding an MBA (Finance), Cost and Management Accountant (ICWA), Company Secretary (CS), and a degree in Law (LLB).	Not Applicable
Disclosure of relationship between Directors (in case of appointment)	Not related to any of the Directors of the Company	Not related to any of the Directors of the Company	Not Applicable
Affirmation	Ms. Kirandeep Madan is not debarred from holding the office of Director by virtue of any SEBI order or	Not Applicable	Not Applicable

MUMBAI OFFICE: Themis House, 11/12 Udyog Nagar, S.V Road, Goregaon (West), Mumbai – 400 104

Tel: 91-22-67607080 / 28757836 Fax: 28746621 / 67607019; E-mail: gtblmumbai@gtbl.in Website Address: www.gtbl.in



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE,
VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA

TEL: 0260-2430027 / 2400639

E-mail: hrm@gtbl.in

	any other such authority. She has not been convicted of any offence in connection with the promotion, formation or management of any Company or LLP, nor found guilty of any fraud, misfeasance or breach of duty to any Company under the Companies Act, 2013 or any previous Companies Act in the last five years.		
--	--	--	--

GUJARAT THEMIS BIOSYN LIMITED
CIN: L24230GJ1981PLC004878
69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat
Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.in.net Website: www.gtbl.in

Statement of Unaudited Financial Results for the Quarter and Nine month ended December 31, 2025

(Amount in INR Lakhs)

Sr. No.	PARTICULARS	Quarter Ended			Nine Month		Year Ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Income from operations	4,336.82	4,234.88	3,951.98	12,158.98	11,306.37	15,079.99
II	Other Income	41.62	81.63	24.17	150.70	108.47	243.24
III	Total Income (I+II)	4,378.45	4,316.51	3,976.15	12,309.68	11,414.84	15,323.23
IV	Expenditure						
	(a) Cost of raw material consumed	662.40	692.39	655.39	2,037.38	1,892.57	2,577.72
	(b) Purchases of stock-in-trade			-	-	-	-
	(c) Changes in inventories of Finished Goods, Work-in-	(79.85)	(153.06)	43.97	(252.80)	(64.65)	(127.23)
	(d) Employee benefits expense	475.68	484.78	302.36	1,271.65	950.42	1,264.11
	(e) Finance Cost	96.04	4.04	14.45	104.29	29.25	36.40
	(f) Depreciation and Amortisation expenses	388.81	295.90	156.33	888.09	414.69	537.49
	(g) Other Expenses	-	-				
	i) Stores and spares	142.09	204.19	186.65	483.25	524.90	737.32
	ii) Power	607.42	541.41	525.80	1,666.49	1,507.06	1,997.36
	iii) Fuel	140.30	126.97	141.09	413.95	419.55	563.90
	iv) Water	30.06	25.49	25.07	84.15	73.89	102.21
	v) Other expenditure	228.16	218.34	185.00	837.86	722.09	1,080.16
	Total Expenses	2,691.11	2,440.46	2,236.11	7,534.32	6,469.78	8,769.44
V	Profit/(Loss) before Exceptional Items and Tax (III-IV)	1,687.34	1,876.05	1,740.04	4,775.36	4,945.07	6,553.79
VI	Exceptional items		-	-		-	-
VII	Profit/(Loss) before Tax (V-VI)	1,687.34	1,876.05	1,740.04	4,775.36	4,945.07	6,553.79
VIII	Tax expenses						
	(a) Current Tax	286.12	308.31	443.99	841.08	1,262.85	1,669.62
	(b) Deferred Tax	154.76	141.34	(1.19)	355.25	4.86	28.05
	(c) Income Tax of earlier years		-	-	-	-	(21.05)
IX	Net Profit/(Loss) after tax (VII-VIII)	1,246.46	1,426.40	1,297.23	3,579.03	3,677.35	4,877.17
X	Other Comprehensive Income						
	Items that will not be reclassified to Profit or Loss						
	(i) remeasurement of defined benefit plans;	(3.29)	1.70	(11.15)	0.11	(0.95)	6.81
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	0.83	(0.43)	2.81	(0.03)	0.24	(1.71)
XI	Total Comprehensive Income for the period (IX+X)	1,244.00	1,427.67	1,288.89	3,579.11	3,676.65	4,882.27
XII	Paid-up equity share capital	1,089.65	1,089.65	1,089.65	1,089.65	1,089.65	1,089.65
XIII	Other Equity						23,748.54
XIV	Earnings Per Share (Basic and Diluted)	1.14	1.31	1.19	3.28	3.37	4.48



Notes:

- 1 The financial results for the quarter and year ended December 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 05, 2026.
- 2 The Company operates only in one Business Segment i.e. manufacturing Bulk Drugs, hence does not have any reportable segments as per Indian Accounting Standard (Ind AS)-108 "Operating Segments".
- 3 The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.
- 4 On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Codes have been made effective from November 21, 2025. The incremental impact of these changes, assessed by the Company, on the basis of the information available, consistent with the guidance provided by the Institute of Chartered Accountants of India, is INR 13.36 lakhs. This amount has been recognized in the financial results of the Company for the quarter and nine months ended December 31, 2025. Once Central/State Rules are notified by the Government on all aspects of the Codes, the Company will evaluate impact, if any, on the measurement of employee benefits and would provide appropriate accounting treatment.
- 5 Figures of previous periods/years' have been regrouped / rearranged, wherever considered necessary.

Place: Mumbai
Date : February 05, 2026



For GUJARAT THEMIS BIOSYN LIMITED

Dr. DINESH PATEL
Chairman
DIN : 00033273

Independent Auditor's Review report on Quarterly Unaudited Financial Results and Year to Date Results Of Gujarat Themis Biosyn Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review report to

The Board of Directors

GUJARAT THEMIS BIOSYN LIMITED

We have reviewed the accompanying statement of Unaudited financial results of **Gujarat Themis Biosyn Limited** ('the Company') for the quarter ended December 31, 2025 and year to date from April 1, 2025 to December 31, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulation").

This statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Based on our review, conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable Indian Accounting Standards prescribed under section 133 of Companies Act 2013 read with rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For GMJ & Co

Chartered Accountants

FRN: 103429W



CA Amit Maheshwari

Partner

M. No.: 428706

UDIN : 264287 06PRKN MK6041



Place : Mumbai

Date : February 05, 2026

Date: 5th February, 2026

To,

The Board of Directors

Gujarat Themis Biosyn Limited

69/C, GIDC Industrial Estate,

Vapi – 396 195, Dist. Valsad, Gujarat.

Dear Sir / Madam,

Sub: Stepping down from the position of Chief Financial Officer & Key Managerial Personnel (KMP):

I am presently working as the Chief Financial Officer and Key Managerial Personnel (KMP) of the Company.

As I am transitioning into different role within the Company to focus on handling plant-related accounting activities including ongoing projects. I hereby step down from the position of Chief Financial Officer and KMP of the Company with effect from 1st April, 2026.

I would like to inform you that I shall continue to serve the Company in my new role as Senior Accounts Manager with effect from 1st April, 2026.

I take this opportunity to thank the Management and the Board of Directors for the support and cooperation extended to me during my tenure as Chief Financial Officer and KMP of the Company.

I request you to kindly accept my resignation and relieve me from the duties of Chief Financial Officer and KMP after the close of working hours on 31st March, 2026.

I wish the Company continued success and all the very best.

Thanking you.

Yours sincerely,



Bhavik Shah

Chief Financial Officer